financetom
Business
financetom
/
Business
/
Indian parliament suspended again in row over U.S. accusations against Adani
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indian parliament suspended again in row over U.S. accusations against Adani
Nov 26, 2024 11:09 PM

NEW DELHI, Nov 27 (Reuters) - India's lower house of

parliament suspended proceedings for a second day on Wednesday

after disruption by lawmakers calling for a discussion of U.S.

accusations of bribery and fraud against the ports-to-power

Adani Group.

Gautam Adani, the billionaire founder of the conglomerate,

his nephew Sagar Adani and six others have been charged for

their alleged roles in a $265-million scheme to bribe Indian

officials to win solar power supply deals in five regions.

The Adani Group has denied the charges as "baseless" and

vowed to "seek all possible legal recourse".

Indian opposition parties, especially the Congress, have

accused Prime Minister Narendra Modi and his Bharatiya Janata

Party (BJP) of shielding Adani and blocking investigations

against him in India. They deny the accusations.

Parliament proceedings were disrupted for the second day

since the winter session began this week, with members shouting

slogans and demanding discussion of the Adani allegations.

Congress leader Rahul Gandhi, who has been a vocal critic of

Adani, said Gautam Adani should be arrested.

"The gentleman has been indicted in the United States ...

and the government is protecting him," Gandhi told reporters

outside parliament.

The government has made no comment on the indictment but the

ruling BJP has distanced itself from the controversy.

The BJP had no reason to defend Gautam Adani, a spokesperson

said on Tuesday.

"Let him defend himself," said the spokesperson, Gopal

Krishna Agarwal. "We are not against industrialists. We consider

them as partners in nation-building. But the law will take its

own course if they do something wrong."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chevron agrees Hess CEO will not join board in deal with US regulator, Bloomberg News reports
Chevron agrees Hess CEO will not join board in deal with US regulator, Bloomberg News reports
Sep 26, 2024
(Reuters) - U.S. energy major Chevron ( CVX ) has agreed Hess CEO John Hess will not join its board in an agreement with the U.S. Federal Trade Commission to proceed with the $53 billion takeover deal, Bloomberg News reported on Thursday citing people familiar with the matter. The proposed all-stock acquisition, first announced in October, is one of the...
Market Chatter: Super Micro Computer Reportedly Gets Probed by Justice Department; Shares Slump
Market Chatter: Super Micro Computer Reportedly Gets Probed by Justice Department; Shares Slump
Sep 26, 2024
11:33 AM EDT, 09/26/2024 (MT Newswires) -- Super Micro Computer ( SMCI ) shares were down over 12% Thursday after the Wall Street Journal reported the company is being probed by the US Department of Justice over accusations of accounting violations made by a former employee. The probe is in an early stage, the WSJ said citing people familiar with...
Evergrande EV unit's liquidators still in talks with potential stake buyers
Evergrande EV unit's liquidators still in talks with potential stake buyers
Sep 26, 2024
(Reuters) -Liquidators of the electric vehicle arm of debt-laden China Evergrande are still in talks with a potential buyer to take a stake in the company with a view to provide a new credit line to support production. In its initial days, the electric vehicle maker aimed to take on Tesla and had a market valuation higher than Ford Motor,...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Sep 26, 2024
By Kashish Tandon and Christy Santhosh (Reuters) - Pfizer's ( PFE ) decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said. Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms....
Copyright 2023-2026 - www.financetom.com All Rights Reserved